Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00826020 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Omegaven™ Parenteral Nutrition in Patients With Total Parenteral Nutrition (TPN)-Induced Cholestasis
A Phase 2 study, sponsored by University of Nebraska.
- Completed
- Registry status
- Phase 2
- Development phase
- 72
- Enrollment target
NCT00826020 is a Phase 2 study that has completed, run by University of Nebraska. The registered enrollment target is 72 participants.
The verdict
NCT00826020, a Phase 2 study, has completed, sponsored by University of Nebraska.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 72 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if established parenteral nutrition (PN) associated liver disease can be reversed or its progression halted by using a parenteral fat emulsion prepared from fish oil as measured by normalization of serum levels of hepatic enzymes and bilirubin.
Interventions
- DRUG Omegaven™
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2009-05-01 |
| Est. Completion | 2017-10-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00826020
The ClinicalTrials.gov registry entry for NCT00826020 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Nebraska, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Omegaven™ is the first listed.
NCT00826020 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00826020 about?
NCT00826020 is a clinical study titled "Evaluation of Omegaven™ Parenteral Nutrition in Patients With Total Parenteral Nutrition (TPN)-Induced Cholestasis". The purpose of this study is to determine if established parenteral nutrition (PN) associated liver disease can be reversed or its progression halted by using a parenteral fat emulsion prepared from fish oil as measured by normalization of serum levels of hepatic enzymes and bilirubin.
What is the current status of trial NCT00826020?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2009-05-01. Estimated completion is 2017-10-06.
What interventions are being tested in trial NCT00826020?
The interventions under investigation include: Omegaven™ (DRUG).
Who is sponsoring clinical trial NCT00826020?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.